Nebenwirkungen · Uptravi
Uptravi 100 microgram film-coated tablets Uptravi 200 microgram film-coated tablets Uptravi 400 microgram film-coated tablets Uptravi 600 microgram film-coated tablets Uptravi 800 microgram film-coated tablets Uptravi 1 000 microgram film-coated tablets Uptravi 1 200 microgram film-coated tablets Uptravi 1 400 microgram film-coated tablets Uptravi 1 600 microgram film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-131275 · Präparat HOS-097037
In a phase 3 placebo-controlled study in patients newly diagnosed with PAH, mean absolute changes in haemoglobin at regular visits compared to baseline ranged from 1.77 to 1.26 g/dL in the triple therapy group (selexipag, macitentan, tadalafil) compared to 1.61 to 1.28 g/dL in the double therapy group (placebo, macitentan and tadalafil). A decrease from baseline in haemoglobin concentration to below 10 g/dL was reported in 19.0% of patients in the triple therapy group and 14.5% in the double therapy group. Anaemia was reported with very common frequency (13.4%) in the triple therapy group compared to common frequency (8.3%) in the double therapy group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T09:30:00Z · SHA-256 4d844da5fca00693ca71123bccf29f73c6fef6cc58001bcf22168f0e68d3056f · Passage 99aa69ea5eb28368fa2af2a7ce2f7a24bab5e1d7f842361995709cf28682bca5 · Zeichen 5558–6222 im Abschnitt